MediciNova is a biopharmaceutical company focused on developing innovative therapies for patients with significant unmet medical needs, with lead programs targeting neurodegenerative diseases, including ALS and progressive multiple sclerosis. Pulse 2.0 interviewed MediciNova Founder and CEO Dr. Yuichi Iwaki to learn more.
Dr. Yuichi Iwaki’s Background
Could you tell me more about your background? Iwaki said:
“My career has really centered on understanding the immune system and figuring out how to turn scientific insights into therapies that better help patients. I earned both my M.D. and Ph.D. from Sapporo Medical School in Japan, and I began my academic career at UCLA in 1977, where I focused on transplantation medicine. Later, at the University of Pittsburgh, I led the Transplant Immunology Laboratory and worked on major clinical trials that helped bring forward drugs like Cyclosporin and Prograf, treatments that significantly improved outcomes for transplant patients. Those experiences showed me how powerful it can be when research translates into something that changes lives. I eventually joined the University of Southern California School of Medicine, where I continue to teach and run the Transplantation Immunology and Immunogenetic Laboratory. Over the years, I have also published extensively and served as an advisor to biotechnology companies and investors, which allowed me to see drug development from multiple angles.”
“All of that experience ultimately shaped the vision for MediciNova. I kept seeing large, unmet medical needs, especially in neurodegenerative diseases like ALS and progressive multiple sclerosis, where patients had very few options and the field needed fresh thinking. Because I had spent decades working at the intersection of science, clinical care, and biotech strategy, founding MediciNova in 2000 felt like a natural step. The goal for our Company from the beginning was straightforward: build a team capable of developing innovative therapies for conditions where the medical community urgently needs better answers. That mission still guides us today.”
Formation Of The Company
How did the idea for the company come together? Iwaki shared:
“The idea for MediciNova really emerged from a series of conversations throughout my career. After being closely involved in clinical trials that changed the field of transplantation, people would often ask why I wasn’t leading similar efforts in other therapeutic areas, especially those where medicine had very limited answers. Clinicians, researchers, and industry colleagues frequently encouraged me to take a more central role in drug development because they saw the potential to apply the same scientific discipline and clinical insight to other unmet needs.”
“Over time, it became clear that I had a unique combination of perspectives — deep academic experience, hands-on clinical trial involvement, and strategic insight from working with industry. Founding MediciNova felt like a natural extension of everything I had been doing up to that point. The goal was to build a company capable of developing therapies for diseases where progress had been slow and patients were still waiting. That mission remains at the heart of MediciNova.”
Core Products
What are the company’s core products and what do they target? Iwaki explained:
“MediciNova’s work is centered around two key compounds: MN-166 and MN-001, each designed to address major unmet medical needs.”
“MN-166 is focused on neurodegenerative diseases, including ALS and multiple sclerosis. These conditions place a heavy burden on patients and families, and they come with limited treatment options that often slow progression only modestly. MN-166’s potential lies in its ability to target pathways that contribute to inflammation and neurodegeneration. The goal is to offer a therapy that can meaningfully alter the course of these diseases rather than just manage symptoms.”
“MN-001 addresses a very different but equally important set of issues. It may have the ability to help patients with lipid metabolism abnormalities and to reduce fibrosis, a factor that contributes to long-term disease progression in several chronic conditions. The compound could potentially open the door to new treatment strategies by taking mechanisms that are scientifically sound and applying them to diseases where effective solutions simply don’t exist today.”
“Together, these two compounds represent a targeted, science-driven approach to drug development for some of the most challenging and underserved conditions in medicine.”
Challenges Faced
Have you faced any challenges in this line of work recently? Iwaki acknowledged:
“Challenges are part of daily life in drug development, especially in fields like ALS, where the science is evolving quickly, and the patient population is incredibly vulnerable. Every phase of research, from refining biomarkers to engaging with regulatory agencies, presents new complexities. Neurodegenerative diseases are particularly difficult because they involve multiple pathways and designing clinical trials that accurately capture meaningful benefit requires careful planning.”
“Despite this, we remain committed to advancing the science one step at a time. Each challenge helps us better understand the disease and refine our approach. Until a therapy reaches FDA approval, there will always be obstacles, but our team continues to navigate them with a focus on generating strong, data-driven evidence.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Iwaki noted:
“The evolution has been steady and thoughtful. When we began, there wasn’t a clear roadmap for how these compounds would ultimately be positioned or how the data would develop over time. Much of drug development requires following the science, not forcing it, and that’s exactly what we’ve done.”
“As the clinical data accumulated, our understanding of the compounds grew significantly. We gained confidence not because of assumptions, but because each new data point reinforced the underlying science. It takes years of persistence to build a truly data-driven program, but that commitment has shaped everything about MediciNova’s approach.”
“What we’re doing now reflects a deep belief that these drugs have real potential to address unmet needs. The science has validated itself step by step, and that’s allowed us to refine our focus, adjust our strategies, and build a development path grounded in evidence rather than theory.”
Significant Milestones
What have been some of the company’s most significant milestones? Iwaki cited:
“One of our most meaningful milestones was the completion of the Phase 2/3 clinical trial in ALS. This was a major undertaking, and completing the study without significant adverse events was an encouraging outcome. ALS is a devastating disease, and the safety profile of a potential therapy matters just as much as its effectiveness. To reach that point without major safety concerns is a testament to the strength of the underlying science.”
“For a company working in areas with high unmet need, milestones like these are incredibly important. They mark not only scientific progress but also a step closer to giving patients access to a therapy that could make a tangible difference. Completing this trial has provided us with a strong foundation to move forward into the next phase of development with confidence.”
Differentiation From The Competition
What differentiates the company from its competition? Iwaki affirmed:
“In many respects, we’re operating in an area with limited direct competition. The mechanisms we’re pursuing, and the specific features of our lead compound are unique. That creates a different kind of opportunity, one where the company’s success doesn’t depend on outperforming dozens of similar therapies, but rather on proving the clinical value of an approach that others aren’t taking.”
“Our differentiation comes from the uniqueness of the science and the clarity of focus. Instead of racing to be slightly better than existing treatments, we’re targeting conditions and pathways where the current options simply aren’t good enough. That mindset shapes everything we do and sets us apart from others in the field.”
Future Company Goals
What are some of the company’s future goals? Iwaki concluded:
“Our primary goal is to continue advancing MN-166 in ALS and to evaluate the appropriate regulatory pathway based on the totality of clinical data, which represents an important milestone not just for the company but for the broader patient community. Completing that step is a top priority, and it represents years of scientific work and clinical progress.”
“Looking ahead, we’re also focused on expanding the reach of MN-166. Once the ALS filing is complete, we plan to pursue additional applications, including progressive multiple sclerosis. The long-term vision is to create a therapy that can benefit multiple patient populations who currently have limited options. If we can extend the impact of MN-166 in a thoughtful, scientifically rigorous way, the potential to help more patients becomes even greater.”
